These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10695820)

  • 1. Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study.
    Mulne AF; Ducore JM; Elterman RD; Friedman HS; Krischer JP; Kun LE; Shuster JJ; Kadota RP
    J Pediatr Hematol Oncol; 2000; 22(1):41-4. PubMed ID: 10695820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study.
    Hurwitz CA; Strauss LC; Kepner J; Kretschmar C; Harris MB; Friedman H; Kun L; Kadota R
    J Pediatr Hematol Oncol; 2001; 23(5):277-81. PubMed ID: 11464982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
    Nicholson HS; Kretschmar CS; Krailo M; Bernstein M; Kadota R; Fort D; Friedman H; Harris MB; Tedeschi-Blok N; Mazewski C; Sato J; Reaman GH
    Cancer; 2007 Oct; 110(7):1542-50. PubMed ID: 17705175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose methotrexate with citrovorum factor rescue for the treatment of central nervous system tumors in children.
    Rosen G; Ghavimi F; Nirenberg A; Mosende C; Mehta BM
    Cancer Treat Rep; 1977 Jul; 61(4):681-90. PubMed ID: 301781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 study of idarubicin in pediatric brain tumors: Pediatric Oncology Group study POG 9237.
    Dreyer ZE; Kadota RP; Stewart CF; Friedman HS; Mahoney DH; Kun LE; McCluggage CW; Burger PC; Kepner J; Heideman RL;
    Neuro Oncol; 2003 Oct; 5(4):261-7. PubMed ID: 14565163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topotecan for the treatment of recurrent or progressive central nervous system tumors - a pediatric oncology group phase II study.
    Kadota RP; Stewart CF; Horn M; Kuttesch JF; Burger PC; Kepner JL; Kun LE; Friedman HS; Heideman RL
    J Neurooncol; 1999 May; 43(1):43-7. PubMed ID: 10448870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin in recurrent pediatric brain tumors. A POG Phase II study. A Pediatric Oncology Group Study.
    Sexauer CL; Khan A; Burger PC; Krischer JP; van Eys J; Vats T; Ragab AH
    Cancer; 1985 Oct; 56(7):1497-501. PubMed ID: 4040799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia.
    Maiguma T; Hayashi Y; Ueshima S; Kaji H; Egawa T; Chayama K; Morishima T; Kitamura Y; Sendo T; Gomita Y; Teshima D
    Int J Clin Pharmacol Ther; 2008 Nov; 46(11):584-90. PubMed ID: 19000557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [High dose chemotherapy with thiotepa, carboplatin, VP16 and autologous stem cell transplantation in treatment of malignant brain tumors with poor prognosis. Results of a mono-center pilot study].
    Fleischhack G; Pöpping K; Hasan C; Utsch B; Jüttner J; Bode U
    Klin Padiatr; 1998; 210(4):248-55. PubMed ID: 9743961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II evaluation of thiotepa in pediatric central nervous system malignancies.
    Heideman RL; Packer RJ; Reaman GH; Allen JC; Lange B; Horowitz ME; Steinberg SM; Gillespie A; Kovnar EH; Balis FM
    Cancer; 1993 Jul; 72(1):271-5. PubMed ID: 8508417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
    Turner CD; Gururangan S; Eastwood J; Bottom K; Watral M; Beason R; McLendon RE; Friedman AH; Tourt-Uhlig S; Miller LL; Friedman HS
    Neuro Oncol; 2002 Apr; 4(2):102-8. PubMed ID: 11916501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global methylation in relation to methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia.
    Oosterom N; Griffioen PH; den Hoed MAH; Pieters R; de Jonge R; Tissing WJE; van den Heuvel-Eibrink MM; Heil SG
    PLoS One; 2018; 13(7):e0199574. PubMed ID: 29985926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections.
    Wright KD; Panetta JC; Onar-Thomas A; Reddick WE; Patay Z; Qaddoumi I; Broniscer A; Robinson G; Boop FA; Klimo P; Ward D; Gajjar A; Stewart CF
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):27-35. PubMed ID: 25342291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.
    Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B
    J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aziridinylbenzoquinone (AZQ) in the treatment of recurrent pediatric brain and other malignant solid tumors. A Pediatric Oncology Group phase II study.
    Castleberry RP; Ragab AH; Steuber CP; Kamen B; Toledano S; Starling K; Norris D; Burger P; Krischer JP
    Invest New Drugs; 1990 Nov; 8(4):401-6. PubMed ID: 2084075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas.
    Hiraga S; Arita N; Ohnishi T; Kohmura E; Yamamoto K; Oku Y; Taki T; Sato M; Aozasa K; Yoshimine T
    J Neurosurg; 1999 Aug; 91(2):221-30. PubMed ID: 10433310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study.
    Mahoney DH; Shuster JJ; Nitschke R; Lauer S; Steuber CP; Camitta B
    J Clin Oncol; 2000 Mar; 18(6):1285-94. PubMed ID: 10715299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors.
    Terasaki M; Bouffet E; Katsuki H; Fukushima S; Shigemori M
    Surg Neurol; 2008 Jan; 69(1):46-50. PubMed ID: 18054615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study.
    Kieran MW; Packer RJ; Onar A; Blaney SM; Phillips P; Pollack IF; Geyer JR; Gururangan S; Banerjee A; Goldman S; Turner CD; Belasco JB; Broniscer A; Zhu Y; Frank E; Kirschmeier P; Statkevich P; Yver A; Boyett JM; Kun LE
    J Clin Oncol; 2007 Jul; 25(21):3137-43. PubMed ID: 17634493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage chemotherapy for recurrent primary brain tumors in children.
    van Eys J; Baram TZ; Cangir A; Bruner JM; Martinez-Prieto J
    J Pediatr; 1988 Sep; 113(3):601-6. PubMed ID: 3411410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.